Product Description
Mechanisms of Action: TGFR Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Stryker
Company Location: KALAMAZOO MI 49002
Company CEO: Kevin A. Lobo
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Other|Tibial Fractures
Phase 3: Pain Unspecified
Phase 2: Cleft Palate|Cleft Lip|Femoral Neck Fractures|Femoral Fractures
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02655120 |
BMP7 | N/A |
Terminated |
Femur Head Necrosis |
2017-05-01 |
2019-03-20 |
Treatments |
|
2005-004392-38 |
The use of BMP for alveolar reconstruction | P2 |
Terminated |
Cleft Palate|Cleft Lip |
2010-11-01 |
2022-03-12 |
Treatments |
|
2005-004149-33 |
2005-004149-33 | P2 |
Terminated |
Femoral Neck Fractures|Femoral Fractures |
2008-09-30 |
2022-03-12 |
Treatments |
|
2004-000675-34 |
2004-000675-34 | P3 |
Active, not recruiting |
Pain Unspecified |
2007-05-27 |
2022-03-12 |
Treatments |
|
2006-006727-39 |
2006-006727-39 | P4 |
Completed |
Unknown |
2015-10-18 |
2025-07-09 |
Treatments |
|
NCT00551941 |
NCT00551941 | P4 |
Terminated |
Tibial Fractures |
2012-07-09 |
2021-07-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2006-001725-25 |
ACETABULAR BONE GRAFTING SUBSTITUTES IN REVISION HIP SURGERY | P4 |
Terminated |
Other |
2007-08-06 |
2022-03-12 |
Treatments |